Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label tisagenlecleucel study in relapsed or refractory follicular lymphoma
NL-OMON55846Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in follicular lymphoma (FL), sponsored by Novartis. Primary endpoint: Complete response rate. Started Sep 2019; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON55846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55846.